The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
100 jobs Number of planned job creations
Announcement Date
17 September 2015
Employment effect (start)
17 September 2015
Foreseen end date
31 December 2015
Description
Sandoz, world leader in developing and manufacturing generic pharmaceuticals and part of the Swiss Novartis Group, has opened a new production plant in Schaftenau (Tyrol) creating 100 new high-skilled jobs. At the plant ready-to-fill syringes and auto-injections for Novartis and Sandoz “biosimilars” will be produced, which are cheaper versions of biopharmaceutical products after their patent has expired. Biosimilars are typically used to treat cancer and auto-immune diseases.
Sources
17 September 2015: Wirtschaftsblatt
18 September 2015: Tiroler Tageszeitung
17 September 2015: orf online
Citation
Eurofound (2015), Sandoz, Business expansion in Austria, factsheet number 84831, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/84831.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
